VASRD 7123 · Cardiovascular / Lymphatic System

Soft Tissue Sarcoma (of Vascular Origin) VA Disability Rating

DC 7123 covers soft tissue sarcoma of vascular origin — a cancer arising in blood vessel tissue. The code has one evaluation and one only: 100 percent. Its Note keeps that 100 percent in place beyond the end of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, and sets a mandatory VA examination six months after that treatment is discontinued. If there has been no local recurrence or metastasis by then, the evaluation is made on the residuals that remain.

VA Rating Tiers

RatingCriteria
100%A soft tissue sarcoma of vascular origin is rated 100 percent, and that rating continues through treatment. Six months after treatment stops, a mandatory VA examination decides the rating; if the cancer has not returned or spread, the rating moves to whatever residuals remain, and any reduction is protected by the § 3.105(e) procedure.

How the VA Evaluates Soft Tissue Sarcoma (of Vascular Origin)

DC 7123 has one criterion and one percentage: soft tissue sarcoma (of vascular origin) is evaluated at 100 percent. There are no lower bands and no measurements — nothing about the size or site of the tumor, and nothing about swelling, infections, or response to therapy. The code's Note governs everything that follows treatment. A rating of 100 percent continues beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating is determined by mandatory VA examination, and any change in evaluation based upon that or any subsequent examination is subject to the provisions of § 3.105(e). If there has been no local recurrence or metastasis, the evaluation is made on residuals. The code does not itself name which residuals or which codes they are evaluated under; what it fixes is the 100 percent while the disease is active and through treatment, the six-month mandatory examination once treatment stops, and the switch to residuals where there has been no local recurrence or metastasis.

Veterans service-connected

~300 veterans

Vetrify editorial estimates informed by VA published claims data (VBA Annual Benefits Report) and the VA rating schedule — not official VA statistics.

Email me this Soft Tissue Sarcoma (of Vascular Origin) guide

Get the Soft Tissue Sarcoma (of Vascular Origin) rating criteria, evidence checklist, and strategy tips delivered to your inbox so you can review them anytime.

We’ll email what you asked for, plus occasional Vetrify updates and practical VA disability education. Unsubscribe anytime with the one-click link in every email.

Best Evidence to Gather

  • Pathology reports establishing the diagnosis of soft tissue sarcoma and its vascular origin, which is what DC 7123 is written for.
  • Oncology treatment records showing the dates of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, and the date treatment was discontinued.
  • Follow-up imaging and oncology notes stating whether there has been local recurrence or metastasis.
  • Operative reports documenting what was removed or reconstructed, which is what any residual impairment is built from.
  • Post-treatment records documenting the residuals that remain, since these carry the evaluation once the mandatory VA examination has been held.

Strategy Tips

  • Keep the date treatment was discontinued clearly documented — surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure — since the Note runs the six months to the mandatory VA examination from that point.
  • Have oncology follow-up address local recurrence and metastasis in so many words. That finding is the dividing line between the 100 percent continuing and the evaluation moving to residuals.
  • Build the post-treatment record around what remains after the sarcoma and its treatment. Once the mandatory examination has been held and there has been no local recurrence or metastasis, residuals are what the evaluation rests on.
  • Expect the evaluation to be revisited rather than fixed: the Note makes any change based on that examination, or any subsequent one, subject to the provisions of § 3.105(e).

C&P Exam Pitfalls

  • Reaching the six-month mandatory examination with no post-treatment workup in the file, leaving the examiner nothing to assess residuals on.
  • A record that documents the sarcoma and its treatment but never states whether there has been local recurrence or metastasis, which is the fact the Note turns on.
  • Treatment dates left vague, so the six months after discontinuance of treatment cannot be fixed from the record.
  • Residuals described only in relation to the cancer, with no account of the specific functions affected, when the evaluation after the mandatory examination is made on residuals.

Common Filing Mistakes

  • Treating the 100 percent as permanent. The Note continues it beyond the cessation of treatment, but sets a mandatory VA examination six months after treatment is discontinued, with any change subject to § 3.105(e).
  • Letting the file go quiet once treatment ends, leaving no residual documentation for the examination the Note schedules.
  • Filing this as a swelling or lymphatic claim. DC 7123 is a malignancy code and its sole criterion is soft tissue sarcoma of vascular origin, evaluated at 100 percent.
  • Assuming the sarcoma diagnosis continues to control after the mandatory examination, when the Note directs the evaluation to residuals where there has been no local recurrence or metastasis.

Onset Patterns

  • The schedule follows a fixed sequence for this code rather than a symptom progression: the sarcoma is evaluated at 100 percent, treatment ends, the 100 percent continues beyond the cessation of that treatment, a mandatory VA examination falls six months after discontinuance, and the evaluation then rests on residuals if there has been no local recurrence or metastasis.
  • Where there has been no local recurrence or metastasis, residuals carry the evaluation from that point forward, so the findings recorded after treatment — not the sarcoma diagnosis itself — determine the percentage.

Common questions about Soft Tissue Sarcoma (of Vascular Origin)

Is Soft Tissue Sarcoma (of Vascular Origin) a VA-rated disability?
Yes. The VA rates Soft Tissue Sarcoma (of Vascular Origin) under VASRD diagnostic code 7123 (Cardiovascular / Lymphatic System). DC 7123 covers soft tissue sarcoma of vascular origin — a cancer arising in blood vessel tissue. The code has one evaluation and one only: 100 percent. Its Note keeps that 100 percent in pla…
What VA disability rating can I get for Soft Tissue Sarcoma (of Vascular Origin)?
Possible VA ratings for Soft Tissue Sarcoma (of Vascular Origin) are 100%. Examples: 100%: A soft tissue sarcoma of vascular origin is rated 100 percent, and that rating continues through treatment. Six months after treatment stops, a mandatory VA examination decides the rating; if the cancer has not returned or sprea…
What evidence helps prove Soft Tissue Sarcoma (of Vascular Origin) for VA disability?
Strong evidence for a Soft Tissue Sarcoma (of Vascular Origin) claim includes: Pathology reports establishing the diagnosis of soft tissue sarcoma and its vascular origin, which is what DC 7123 is written for.; Oncology treatment records showing the dates of any surgical, X-ray, antineoplastic chemotherapy or other th…
What mistakes should veterans avoid when claiming Soft Tissue Sarcoma (of Vascular Origin)?
Common pitfalls when filing for Soft Tissue Sarcoma (of Vascular Origin): Treating the 100 percent as permanent. The Note continues it beyond the cessation of treatment, but sets a mandatory VA examination six months after treatment is discontinued, with any change subject to § 3.105(e).; Letting the file go quiet onc…

Official sources

  1. 38 CFR § 4.104 — Schedule of ratings — cardiovascular system (Diagnostic Code 7123)

Rating criteria on this page are an educational summary of the cited regulation — the eCFR text is authoritative. See how Vetrify derives its numbers.

Estimate your combined rating

See how Soft Tissue Sarcoma (of Vascular Origin) combines with your other service-connected conditions using the official VA combined-ratings formula.

Open the calculator
VA Calc: Disability Pay app icon

VA Calc: Disability Pay

Combine your ratings & see monthly pay on your iPhone · Works offline

Download on theApp Store